loading
Schlusskurs vom Vortag:
$4.86
Offen:
$4.7
24-Stunden-Volumen:
158.70K
Relative Volume:
1.39
Marktkapitalisierung:
$38.27M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.4803
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+8.60%
1M Leistung:
-4.95%
6M Leistung:
-57.90%
1J Leistung:
-68.88%
1-Tages-Spanne:
Value
$4.37
$4.91
1-Wochen-Bereich:
Value
$3.85
$4.91
52-Wochen-Spanne:
Value
$3.51
$16.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Firmenname
Karyopharm Therapeutics Inc
Name
Telefon
617-658-0600
Name
Adresse
85 WELLS AVENUE, NEWTON, MA
Name
Mitarbeiter
279
Name
Twitter
@Karyopharm
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
KPTI's Discussions on Twitter

Vergleichen Sie KPTI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
4.43 33.61M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.50 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.19 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-16 Herabstufung H.C. Wainwright Buy → Neutral
2025-07-11 Fortgesetzt H.C. Wainwright Buy
2023-01-19 Eingeleitet Piper Sandler Overweight
2022-11-04 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-09 Hochstufung JP Morgan Underweight → Neutral
2021-11-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-08-06 Herabstufung JP Morgan Overweight → Neutral
2021-08-06 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-08-06 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-07-02 Eingeleitet Morgan Stanley Overweight
2020-03-04 Eingeleitet Barclays Overweight
2020-01-17 Herabstufung Wedbush Outperform → Neutral
2019-07-23 Hochstufung JP Morgan Neutral → Overweight
2019-07-05 Bestätigt H.C. Wainwright Buy
2019-07-05 Bestätigt Robert W. Baird Outperform
2019-03-01 Herabstufung JP Morgan Overweight → Neutral
2019-02-28 Bestätigt BofA/Merrill Underperform
2019-02-27 Herabstufung BofA/Merrill Neutral → Underperform
2019-01-03 Hochstufung BofA/Merrill Underperform → Neutral
2018-12-03 Eingeleitet B. Riley FBR Buy
2018-11-09 Hochstufung Wedbush Neutral → Outperform
2018-05-24 Herabstufung Wedbush Outperform → Neutral
2018-04-02 Fortgesetzt Leerink Partners Outperform
2017-11-15 Fortgesetzt H.C. Wainwright Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2016-09-08 Bestätigt H.C. Wainwright Buy
2016-08-30 Hochstufung Jefferies Hold → Buy
2016-08-18 Eingeleitet H.C. Wainwright Buy
2016-06-28 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

pulisher
Jul 23, 2025

Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Karyopharm Therapeutics Inc. stockConsistent triple-digit returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Karyopharm Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Karyopharm Therapeutics Inc. a good long term investmentSuperior stock selection - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Karyopharm Therapeutics Inc. stock priceBreakneck growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress

Jul 22, 2025
pulisher
Jul 18, 2025

Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada

Jul 16, 2025
pulisher
Jul 15, 2025

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 15, 2025

Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals

Jul 15, 2025
pulisher
Jul 13, 2025

HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm's Freefall: What's Driving the Collapse? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm stock tumbles after disclosing failed financing talks - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Therapeutics Inc reducing workforce by about 20% - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Therapeutics Explores Financing and Strategic Options - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Therapeutics (KPTI) Receives 'Buy' Rating with $27 Pr - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Analyst Initiates Coverage on Karyopharm (KPTI) with Positive Ou - GuruFocus

Jul 11, 2025

Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):